Browse PVRL2

Summary
SymbolPVRL2
Namepoliovirus receptor-related 2 (herpesvirus entry mediator B)
Aliases PVRR2; CD112; HVEB; herpesvirus entry protein B; poliovirus receptor-like 2; CD antigen CD112; Poliovirus re ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type I membrane protein.
Domain PF08205 CD80-like C2-set immunoglobulin domain
PF07686 Immunoglobulin V-set domain
Function

Modulator of T-cell signaling. Can be either a costimulator of T-cell function, or a coinhibitor, depending on the receptor it binds to. Upon binding to CD226, stimulates T-cell proliferation and cytokine production, including that of IL2, IL5, IL10, IL13, and IFNG. Upon interaction with PVRIG, inhibits T-cell proliferation. These interactions are competitive (PubMed:26755705). Probable cell adhesion protein (PubMed:9657005). ; FUNCTION: (Microbial infection) Acts as a receptor for herpes simplex virus 1 (HHV-1) mutant Rid1, herpes simplex virus 1 (HHV-2) and pseudorabies virus (PRV).

> Gene Ontology
 
Biological Process GO:0001675 acrosome assembly
GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0001910 regulation of leukocyte mediated cytotoxicity
GO:0001912 positive regulation of leukocyte mediated cytotoxicity
GO:0001913 T cell mediated cytotoxicity
GO:0001914 regulation of T cell mediated cytotoxicity
GO:0001916 positive regulation of T cell mediated cytotoxicity
GO:0002228 natural killer cell mediated immunity
GO:0002250 adaptive immune response
GO:0002274 myeloid leukocyte activation
GO:0002347 response to tumor cell
GO:0002418 immune response to tumor cell
GO:0002420 natural killer cell mediated cytotoxicity directed against tumor cell target
GO:0002423 natural killer cell mediated immune response to tumor cell
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002456 T cell mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002705 positive regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002708 positive regulation of lymphocyte mediated immunity
GO:0002709 regulation of T cell mediated immunity
GO:0002711 positive regulation of T cell mediated immunity
GO:0002712 regulation of B cell mediated immunity
GO:0002714 positive regulation of B cell mediated immunity
GO:0002715 regulation of natural killer cell mediated immunity
GO:0002717 positive regulation of natural killer cell mediated immunity
GO:0002819 regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002831 regulation of response to biotic stimulus
GO:0002833 positive regulation of response to biotic stimulus
GO:0002834 regulation of response to tumor cell
GO:0002836 positive regulation of response to tumor cell
GO:0002837 regulation of immune response to tumor cell
GO:0002839 positive regulation of immune response to tumor cell
GO:0002855 regulation of natural killer cell mediated immune response to tumor cell
GO:0002857 positive regulation of natural killer cell mediated immune response to tumor cell
GO:0002858 regulation of natural killer cell mediated cytotoxicity directed against tumor cell target
GO:0002860 positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target
GO:0002889 regulation of immunoglobulin mediated immune response
GO:0002891 positive regulation of immunoglobulin mediated immune response
GO:0006997 nucleus organization
GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules
GO:0007157 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules
GO:0007281 germ cell development
GO:0007283 spermatogenesis
GO:0007286 spermatid development
GO:0007289 spermatid nucleus differentiation
GO:0008037 cell recognition
GO:0009566 fertilization
GO:0010927 cellular component assembly involved in morphogenesis
GO:0016050 vesicle organization
GO:0016064 immunoglobulin mediated immune response
GO:0019058 viral life cycle
GO:0019062 virion attachment to host cell
GO:0019064 fusion of virus membrane with host plasma membrane
GO:0019724 B cell mediated immunity
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0030260 entry into host cell
GO:0030382 sperm mitochondrion organization
GO:0031341 regulation of cell killing
GO:0031343 positive regulation of cell killing
GO:0031349 positive regulation of defense response
GO:0033003 regulation of mast cell activation
GO:0033005 positive regulation of mast cell activation
GO:0033363 secretory granule organization
GO:0034330 cell junction organization
GO:0034332 adherens junction organization
GO:0039663 membrane fusion involved in viral entry into host cell
GO:0042267 natural killer cell mediated cytotoxicity
GO:0042269 regulation of natural killer cell mediated cytotoxicity
GO:0042271 susceptibility to natural killer cell mediated cytotoxicity
GO:0043900 regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044406 adhesion of symbiont to host
GO:0044409 entry into host
GO:0044650 adhesion of symbiont to host cell
GO:0044782 cilium organization
GO:0044800 multi-organism membrane fusion
GO:0044803 multi-organism membrane organization
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045216 cell-cell junction organization
GO:0045576 mast cell activation
GO:0045954 positive regulation of natural killer cell mediated cytotoxicity
GO:0046596 regulation of viral entry into host cell
GO:0046718 viral entry into host cell
GO:0046814 coreceptor-mediated virion attachment to host cell
GO:0048232 male gamete generation
GO:0048515 spermatid differentiation
GO:0050792 regulation of viral process
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0051640 organelle localization
GO:0051646 mitochondrion localization
GO:0051654 establishment of mitochondrion localization
GO:0051656 establishment of organelle localization
GO:0051701 interaction with host
GO:0051806 entry into cell of other organism involved in symbiotic interaction
GO:0051828 entry into other organism involved in symbiotic interaction
GO:0060370 susceptibility to T cell mediated cytotoxicity
GO:0061025 membrane fusion
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
GO:1903900 regulation of viral life cycle
Molecular Function GO:0001618 virus receptor activity
GO:0015026 coreceptor activity
GO:0046982 protein heterodimerization activity
GO:0050839 cell adhesion molecule binding
Cellular Component GO:0005913 cell-cell adherens junction
GO:0005915 zonula adherens
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
GO:0043296 apical junction complex
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
hsa04520 Adherens junction
Reactome -
Summary
SymbolPVRL2
Namepoliovirus receptor-related 2 (herpesvirus entry mediator B)
Aliases PVRR2; CD112; HVEB; herpesvirus entry protein B; poliovirus receptor-like 2; CD antigen CD112; Poliovirus re ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PVRL2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPVRL2
Namepoliovirus receptor-related 2 (herpesvirus entry mediator B)
Aliases PVRR2; CD112; HVEB; herpesvirus entry protein B; poliovirus receptor-like 2; CD antigen CD112; Poliovirus re ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PVRL2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPVRL2
Namepoliovirus receptor-related 2 (herpesvirus entry mediator B)
Aliases PVRR2; CD112; HVEB; herpesvirus entry protein B; poliovirus receptor-like 2; CD antigen CD112; Poliovirus re ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PVRL2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2650.284
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5720.813
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0380.983
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1790.638
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0790.974
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3030.92
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2310.576
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4220.77
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0390.981
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9180.645
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7070.814
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 6823001
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PVRL2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPVRL2
Namepoliovirus receptor-related 2 (herpesvirus entry mediator B)
Aliases PVRR2; CD112; HVEB; herpesvirus entry protein B; poliovirus receptor-like 2; CD antigen CD112; Poliovirus re ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PVRL2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPVRL2
Namepoliovirus receptor-related 2 (herpesvirus entry mediator B)
Aliases PVRR2; CD112; HVEB; herpesvirus entry protein B; poliovirus receptor-like 2; CD antigen CD112; Poliovirus re ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PVRL2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PVRL2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPVRL2
Namepoliovirus receptor-related 2 (herpesvirus entry mediator B)
Aliases PVRR2; CD112; HVEB; herpesvirus entry protein B; poliovirus receptor-like 2; CD antigen CD112; Poliovirus re ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PVRL2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPVRL2
Namepoliovirus receptor-related 2 (herpesvirus entry mediator B)
Aliases PVRR2; CD112; HVEB; herpesvirus entry protein B; poliovirus receptor-like 2; CD antigen CD112; Poliovirus re ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PVRL2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPVRL2
Namepoliovirus receptor-related 2 (herpesvirus entry mediator B)
Aliases PVRR2; CD112; HVEB; herpesvirus entry protein B; poliovirus receptor-like 2; CD antigen CD112; Poliovirus re ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PVRL2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPVRL2
Namepoliovirus receptor-related 2 (herpesvirus entry mediator B)
Aliases PVRR2; CD112; HVEB; herpesvirus entry protein B; poliovirus receptor-like 2; CD antigen CD112; Poliovirus re ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PVRL2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.